Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience

Ayalew Tefferi; Naseema Gangat; Mithun Shah; Hassan Alkhateeb; Mrinal S. Patnaik; Aref Al-Kali; Michelle A. Elliott; William J. Hogan; Mark R. Litzow; Christopher C. Hook; Abhishek Mangaonkar; David Viswanatha; Dong Chen; Animesh Pardanani; Rhett P. Ketterling; Kebede H. Begna

doi:10.3324/haematol.2022.281045

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience

Ayalew Tefferi, Naseema Gangat, Mithun Shah, Hassan Alkhateeb, Mrinal S. Patnaik, Aref Al-Kali, Michelle A. Elliott, William J. Hogan, Mark R. Litzow, Christopher C. Hook, Abhishek Mangaonkar, David Viswanatha, Dong Chen, Animesh Pardanani, Rhett P. Ketterling, Kebede H. Begna

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	2474-2479
Number of pages	6
Journal	Haematologica
Volume	107
Issue number	10
DOIs	https://doi.org/10.3324/haematol.2022.281045
State	Published - Oct 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2022.281045

Cite this

Tefferi, A., Gangat, N., Shah, M., Alkhateeb, H., Patnaik, M. S., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Mangaonkar, A., Viswanatha, D., Chen, D., Pardanani, A., Ketterling, R. P., & Begna, K. H. (2022). Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience. Haematologica, 107(10), 2474-2479. https://doi.org/10.3324/haematol.2022.281045

Tefferi, A, Gangat, N, Shah, M, Alkhateeb, H, Patnaik, MS, Al-Kali, A, Elliott, MA, Hogan, WJ , Litzow, MR, Hook, CC, Mangaonkar, A, Viswanatha, D, Chen, D, Pardanani, A, Ketterling, RP & Begna, KH 2022, 'Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience', Haematologica, vol. 107, no. 10, pp. 2474-2479. https://doi.org/10.3324/haematol.2022.281045

@article{fd3d9f1623b04f7f879967975c794b46,

title = "Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience",

author = "Ayalew Tefferi and Naseema Gangat and Mithun Shah and Hassan Alkhateeb and Patnaik, {Mrinal S.} and Aref Al-Kali and Elliott, {Michelle A.} and Hogan, {William J.} and Litzow, {Mark R.} and Hook, {Christopher C.} and Abhishek Mangaonkar and David Viswanatha and Dong Chen and Animesh Pardanani and Ketterling, {Rhett P.} and Begna, {Kebede H.}",

year = "2022",

month = oct,

doi = "10.3324/haematol.2022.281045",

language = "English (US)",

volume = "107",

pages = "2474--2479",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "10",

}

TY - JOUR

T1 - Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia

T2 - a retrospective analysis of the Mayo Clinic experience

AU - Tefferi, Ayalew

AU - Gangat, Naseema

AU - Shah, Mithun

AU - Alkhateeb, Hassan

AU - Patnaik, Mrinal S.

AU - Al-Kali, Aref

AU - Elliott, Michelle A.

AU - Hogan, William J.

AU - Litzow, Mark R.

AU - Hook, Christopher C.

AU - Mangaonkar, Abhishek

AU - Viswanatha, David

AU - Chen, Dong

AU - Pardanani, Animesh

AU - Ketterling, Rhett P.

AU - Begna, Kebede H.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85139535773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139535773&partnerID=8YFLogxK

U2 - 10.3324/haematol.2022.281045

DO - 10.3324/haematol.2022.281045

M3 - Letter

C2 - 35734931

AN - SCOPUS:85139535773

SN - 0390-6078

VL - 107

SP - 2474

EP - 2479

JO - Haematologica

JF - Haematologica

IS - 10

ER -

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this